Turn on more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Sign In
Skip to main content Open accessibility information page
Alert
On January 16, 2024, Governor Phil Murphy signed the New Jersey Data Privacy Law, P.L. 2023, c. 266. The law went into effect on January 15, 2025. Please click on this Frequently Asked Questions link to learn more about the new law and your rights under it.
Alert
On January 8, 2024, Governor Murphy signed into law P.L. 2023, c. 237, which, among other things: amended the Contractors’ Business Registration Act (“CBRA,” formerly the “Contractors’ Registration Act”), N.J.S.A. 56:8-136 et seq., and created the “Home Improvement and Home Elevation Contractor Licensing Act,” N.J.S.A. 45:5AAA-1 et seq. For more information on the registration requirements for contractors and businesses under these laws, click here.
Alert
On July 10, 2024, Governor Murphy signed into law the Real Estate Consumer Protection Enhancement Act, P.L. 2024, c.32, which, among other things, requires sellers of residential property located in New Jersey to use the "Seller's Property Condition Disclosure Statement" ("Disclosure Statement," questions 1 through 108).

Additionally, on July 3, 2023, Governor Murphy signed into law P.L. 2023, c.93, which, among other things, requires sellers of all real property located in New Jersey to make certain additional disclosures concerning flood risks on the "Disclosure Statement." On July 15, 2024, the Division published a "Flood Risk Addendum" to the Disclosure Statement (questions 109 through 117), which includes the additional disclosures concerning flood risks.

As a result of these two laws, effective August 1, 2024:
  • Sellers of residential property must complete the Disclosure Statement (questions 1 through 108). A copy of the Disclosure Statement is available here; and
  • All sellers of real property, both residential and non-residential, must complete the Flood Risk Addendum to the Disclosure Statement (questions 109 through 117). A copy of the Flood Risk Addendum is available here.

The Division has created an instruction sheet with additional information regarding the use of these forms. The forms linked above supersede any forms previously posted by the Division, including, but not limited to, the "Amended Disclosure Statement" posted on December 21, 2023.

Press Release

For Immediate Release:
December 20, 2013

Office of The Attorney General
John J. Hoffman, Acting Attorney General

Division of Consumer Affairs
Eric T. Kanefsky, Director

Division of Law
Christopher S. Porrino, Director
  For Further Information and Media Inquiries:
Jeff Lamm
Neal Buccino
(973) 504-6327
NJ Division of Consumer Affairs Obtains Surrenders of Three Pharmacies' Ability to Dispense Controlled Drugs, Due to Alleged Failure to Comply With State CDS Requirements

NEWARK – New Jersey Acting Attorney General John J. Hoffman and Consumer Affairs Director Eric T. Kanefsky today announced the owners of three pharmacies agreed to the surrender of their ability to possess or sell Controlled Dangerous Substances (CDS), due to the pharmacies' alleged failure to comply with State requirements regarding the dispensing of those drugs.

The three pharmacies are Olde Medford Pharmacy and Medford Family Pharmacy, both owned by Michael Ludwiskowski, and Reiter's Family Pharmacy, located in Ocean Township and owned by Mark Forgang. In separate actions last week, the owners of both pharmacies voluntarily surrendered the State-issued CDS registrations that authorized their pharmacies to handle and dispense controlled medications.

The surrenders resulted from alleged failures to comply with New Jersey's requirements pertaining to controlled substances, which were uncovered during inspections performed by the New Jersey Division of Consumer Affairs' Enforcement Bureau.

All CDS medications have been removed from the three pharmacies. The three stores are now prohibited from possessing, ordering, manufacturing, or distributing any medication that is classified as a Controlled Dangerous Substance. Each store's entrance now bears a notice to the public, indicating that the State has revoked the store's ability to carry or sell controlled drugs.

"Prescription drug diversion fuels addiction, contributes to the demand for heroin, and ruins lives across America. We are using every investigative and enforcement tool available to win this fight," Acting Attorney General Hoffman said. "A doctor's or pharmacist's ability to work with these drugs is not a right, but a privilege granted by the State. It is our duty to revoke that privilege when we find violations of New Jersey's requirements for the responsible management of these drugs."

Pharmacies in New Jersey are licensed by the State Board of Pharmacy. However, no licensed pharmacy may possess or distribute medications classified as Controlled Dangerous Substances, without a CDS registration issued by the State Consumer Affairs Director.

The actions announced today are considered revocations of each pharmacy's CDS registration. If the owners should seek in the future to obtain a new CDS registration, they would need to apply to the Consumer Affairs Director, provide proof that the pharmacy is able to comply with State CDS requirements, and submit to a thorough inspection similar to that required for a new pharmacy.

Attorney General Hoffman noted that the New Jersey Prescription Monitoring Program (NJPMP), administered by the Division of Consumer Affairs, played an important role in the investigations. The NJPMP tracks the prescription sale of all CDS medications dispensed in New Jersey. It provides important information for investigations into pill diversion cases, and assists prescribers and pharmacists as a vital tool for patient care.

The Division of Consumer Affairs' Enforcement Bureau conducted the State's investigations into the three pharmacies, in partnership with the U.S. Drug Enforcement Administration, Medford Township Police Department, Ocean Township Police Department, and Wall Township Police Department. Deputy Attorney General David Puteska, of the Division of Law, is representing the State in these matters.

For more information on the New Jersey Division of Consumer Affairs' initiative to halt the diversion and abuse of prescription drugs, view the Division's NJPMP website at www.NJConsumerAffairs.gov/pmp, and the Division's Project Medicine Drop website at www.NJConsumerAffairs.gov/meddrop.

Consumers who believe they have been cheated or scammed by a business, or suspect any other form of consumer abuse, can file an online complaint with the State Division of Consumer Affairs by visiting its website or by calling 1-800-242-5846 (toll free within New Jersey) or 973-504- 6200.

Follow the Division of Consumer Affairs on Facebook , and check our online calendar of upcoming Consumer Outreach events.

###

Last Modified: 2/27/2015 6:40 AM

Division

Department

State

Legal

RSS

Sign up for New Jersey Division of Consumer Affairs RSS feeds to get the latest information. You can select any category that you are interested in, and any time the website is updated you will receive a notification.

More information about RSS feeds.

Copyright © 2022 State of New Jersey.

OPRA Logo